This technology opportunity provides a method for detecting CTIP2 or CTIP2L and for their use as biomarkers for squamous cell carcinoma. This technology can be used to develop kits for detecting SCC in a patient. The kit can include a CTIP2 and CTIP2L -specific antibody, oligonucleotides, or primers, and a chart or diagram showing biomarker expression values that are expected in the presence of SCC (or a particular stage of SCC). An increase in expression of at least 2-fold relative to a reference value for a sample negative for SCC indicates the presence of SCC in the sample obtained from the subject.
Features & Benefits
- Provides Immunohistochemical (IHC) and PCR based approaches for improved diagnosing and staging of SCC
- Detecting, diagnosing, and staging SCC
- Drug development
Background of Invention
Squamous cell carcinoma (SCC) is a malignant tumor that occurs in many different organs, including the skin, lips, mouth, esophagus, head and neck, urinary bladder, prostate, lungs, breast, vagina, cervix, and ovaries. The current state diagnosing SCC requires a skin biopsy and examination under a microscope.
Patented (U.S. Patent no. 8,071,815). This technology is currently available for exclusive or non-exclusive licensing.